Camlin Fine Sciences LtdQ1 FY27
Camlin Fine Sciences Ltd Q1 FY27 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹104Market Cap: ₹2.0K CrSector: Chemicals & Petrochemicals
Management growth scorecard
Revenue
Category 2
Margin
Category 1
Fundraise
Yes
Order
N/A
Capex
N/A
2 of 3 growth signals are positive.
Full analysisRevenue guidance
Category 2- →Vanillin demand expected to pick up with an estimated 3,000 to 4,000 tons for the year, though production may be limited due to ongoing campaigns (Page 17).
- →Peak vanillin plant utilization aimed at 5,000 tons per year with up to 3 campaigns annually (Page 17).
- →Revenue guidance targets INR2,200 to INR2,300 crores for the full year with EBITDA margins of 10-11% (Page 6).
- →Blends growing at a 20% CAGR, showing strong growth momentum (Page 13).
- →Expected average EBITDA run rate around INR70 crores for coming quarters, with Q3 and Q4 potentially higher (Page 18).
- →Capacity utilization improvements across segments should lead to better EBITDA and revenue growth (Pages 8, 9, 18).
Margin guidance
Category 1- →EBITDA expected to improve by at least 6% if raw material and margin pressures normalize (Page 18).
- →For coming quarters, average EBITDA guidance is around INR70 crores per quarter, with Q2 expected lower and Q3/Q4 higher (Page 18).
- →Company targets INR2,200 to INR2,300 crores in revenue with EBITDA margins of 10% to 11% in FY27 (Page 7).
- →By fiscal 2028, EBITDA margins expected to improve to around 12%-14% (Page 7).
- →Segment growth: blends growing at 20% CAGR, contributing strongly to top line (Page 13).
- →Performance Chemicals EBITDA expected to turn positive from Q2 onwards (Page 10).
- →Raw material cost pressures expected to remain in Q2 but some pass-through to customers is factored; margins to improve as prices stabilize (Page 18 and Page 7).
- →Capital infusion options under review to support growth and balance sheet (Page 12).
Fundraise plans
Yes- →The company is actively exploring options for capital infusion to strengthen the balance sheet but has not finalized any plans yet.
- →They are considering market conditions, interest rates, and credit ratings before deciding on the mode of fundraising.
- →There's discussion about the need for additional working capital lines in the range of INR 100 crores to INR 200 crores to support growth and working capital needs.
- →No immediate decision has been taken on raising equity or new long-term debt, but management is monitoring the situation and will inform stakeholders when a decision is made.
- →Internal cash generation is also being used to manage debt levels, with gross debt slightly reduced from INR 670 crores to INR 640 crores recently.
- →The company aims to avoid hasty decisions and is evaluating the timing and best method to raise funds appropriately.
Order book
The provided pages from the Camlin Fine Sciences Limited earnings call transcript do not explicitly mention details about the current or expected order book or pending orders. However, from the discussion, a few relevant insights can be inferred:
- Demand for vanillin is picking up with an estimated 3,000 to 4,000 tons expected this year, though production may be limited due to campaign constraints.
- There is a supply gap of 5,000 to 6,000 tons in U.S. and Europe markets due to antidumping duties restricting local capacity, offering an opportunity to participate in imports.
- Contract negotiations with fragrance and flavor companies for quarterly, half-yearly, and yearly contracts are progressing well.
- Channel stocks of vanillin have been cleared globally, indicating inventory normalization and improved demand-supply dynamics.
No specific orderbook numbers or pending order values are mentioned in the excerpt.
Capex plans
- →The company is working on alternatives for the diphenol plant, considering new phenolic compounds as potential products. A decision regarding the plant's future use or restart is expected by the third quarter. (Page 6)
- →There is a focus on scaling up vanillin production campaigns, with plans to ideally run up to 3 campaigns a year and reach production capacity of around 5,000 tons, indicating potential capacity investments or utilization of existing capacity. (Page 17)
- →Management is evaluating ways to "sweat" the existing Performance Chemicals plant assets to achieve better margins and returns; options are being finalized in the coming months. (Page 15)
- →Capital raising efforts are underway to support growth and working capital needs, with plans to secure INR100-150 crores of credit lines in the next 1-1.5 months. (Page 16)
- →No immediate large-scale capex is detailed, but strategic decisions around plant utilization and product portfolio are active. (Pages 6, 15, 16)
Track Camlin Fine Sciences Ltd — get its next earnings analysis in your feed
Margin guidance
Category 1- →EBITDA expected to improve by at least 6% if raw material and margin pressures normalize (Page 18).
- →For coming quarters, average EBITDA guidance is around INR70 crores per quarter, with Q2 expected lower and Q3/Q4 higher (Page 18).
- →Company targets INR2,200 to INR2,300 crores in revenue with EBITDA margins of 10% to 11% in FY27 (Page 7).
- →By fiscal 2028, EBITDA margins expected to improve to around 12%-14% (Page 7).
- →Segment growth: blends growing at 20% CAGR, contributing strongly to top line (Page 13).
- →Performance Chemicals EBITDA expected to turn positive from Q2 onwards (Page 10).
- →Raw material cost pressures expected to remain in Q2 but some pass-through to customers is factored; margins to improve as prices stabilize (Page 18 and Page 7).
- →Capital infusion options under review to support growth and balance sheet (Page 12).
Order book
The provided pages from the Camlin Fine Sciences Limited earnings call transcript do not explicitly mention details about the current or expected order book or pending orders. However, from the discussion, a few relevant insights can be inferred:
- Demand for vanillin is picking up with an estimated 3,000 to 4,000 tons expected this year, though production may be limited due to campaign constraints.
- There is a supply gap of 5,000 to 6,000 tons in U.S. and Europe markets due to antidumping duties restricting local capacity, offering an opportunity to participate in imports.
- Contract negotiations with fragrance and flavor companies for quarterly, half-yearly, and yearly contracts are progressing well.
- Channel stocks of vanillin have been cleared globally, indicating inventory normalization and improved demand-supply dynamics.
No specific orderbook numbers or pending order values are mentioned in the excerpt.
How does Camlin Fine Sciences Ltd rank vs peers in Chemicals & Petrochemicals?
Pro feature1Camlin Fine Sciences Ltd
Rev 2Mar 1
See full Chemicals & Petrochemicals sector rankings
How does Camlin Fine Sciences Ltd rank in Chemicals & Petrochemicals?
Compare Camlin Fine Sciences Ltd against every Chemicals & Petrochemicals company (Q1 FY27) on revenue, margins and earnings-call signals.